




23. (New) A solid pharmaceutical dosage form that is not enteric-coated or delayed-released, comprising:


 (a) a proton pump inhibitor (PPI) selected from a group consisting of omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole and leminoprazole; and

(b) at least one buffering agent present in an amount sufficient to prevent or inhibit acid degradation of the PPI by gastric acid so as to achieve bioavailability of the PPI in a subject after oral administration of the dosage form.

 24. (New) The dosage form as recited in Claim 23 wherein the bioavailability of the PPI is sufficient to elicit a therapeutic effect.

 25. (New) The dosage form as recited in Claim 23 wherein the PPI is present in a therapeutically effective amount.

26. (New) The dosage form as recited in Claim 23 wherein the PPI comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

 27. (New) The dosage form as recited in Claim 23 wherein the PPI is omeprazole.

28. (New) The dosage form as recited in Claim 23 wherein the PPI is lansoprazole.

29. (New) The dosage form as recited in Claim 23 wherein the PPI is rabeprazole.

30. (New) The dosage form as recited in Claim 23 wherein the PPI is esomeprazole.

31. (New) The dosage form as recited in Claim 23 wherein the PPI is pantoprazole.

32. (New) The dosage form as recited in Claim 23 wherein the PPI is pariprazole.

33. (New) The dosage form as recited in Claim 23 wherein the PPI is leminoprazole.

34. (New) The dosage form as recited in Claim 23 further comprising at least one flavoring agent.

35. (New) The dosage form as recited in Claim 23 further comprising an anti-foaming agent.

36. (New) The dosage form as recited in Claim 23 wherein the dosage form is a tablet.

37. (New) The dosage form as recited in Claim 23 wherein the dosage form is a powder.

38. (New) The dosage form as recited in Claim 23 wherein the dosage form is a suspension tablet.

39. (New) The dosage form as recited in Claim 23 wherein the dosage form is a chewable tablet.

40. (New) The dosage form as recited in Claim 39 further comprising aspartame.

41. (New) The dosage form as recited in Claim 23 wherein the dosage form is a capsule.

42. (New) The dosage form as recited in Claim 23 wherein the dosage form is an effervescent powder.

Sub 35
43. (New) The dosage form as recited in Claim 23 wherein the dosage form is an effervescent tablet.

44. (New) The dosage form as recited in Claim 23 wherein the dosage form is a plurality of pellets.

45. (New) The dosage form as recited in Claim 23 wherein the dosage form is a plurality of granules.

46. (New) The dosage form as recited in Claim 23 wherein the buffering agent is present in an amount of about 4 mEq to about 30 mEq.

A,
47. (New) The dosage form as recited in Claim 23 wherein the buffering agent is present in an amount of about 7.5 mEq to about 15 mEq.

48. (New) The dosage form as recited in Claim 23 wherein the buffering agent is present in an amount of about 10 mEq to about 20 mEq.

49. (New) The dosage form as recited in Claim 23 wherein the buffering agent comprises a bicarbonate salt of a Group IA metal.

50. (New) The dosage form as recited in Claim 23 wherein the buffering agent comprises at least one of magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium silicate, magnesium lactate, and other magnesium salts.

51. (New) The dosage form as recited in Claim 23 wherein the buffering agent comprises at least one of calcium acetate, calcium glycerophosphate, calcium chloride, calcium

hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, calcium gluconate, calcium glycinate, calcium maleate, and other calcium salts.

52. (New) The dosage form as recited in Claim 23 wherein the buffering agent comprises about 250 mg to about 1680 mg sodium bicarbonate.

53. (New) The dosage form as recited in Claim 23 wherein the buffering agent comprises about 840 mg to about 1680 mg sodium bicarbonate.

54. (New) The dosage form as recited in Claim 23 wherein the buffering agent comprises about 250 mg to about 1000 mg calcium carbonate.

55. (New) The dosage form as recited in Claim 23 wherein the buffering agent comprises about 500 mg to about 1000 mg calcium carbonate.

56. (New) The dosage form as recited in Claim 23 wherein the buffering agent comprises a combination of sodium bicarbonate and calcium carbonate.

57. (New) A liquid pharmaceutical composition produced by the method of combining the dosage form recited in Claim 36 with an aqueous medium.

58. (New) The liquid pharmaceutical composition of Claim 57 wherein the aqueous medium comprises sodium bicarbonate solution.

59. (New) The liquid pharmaceutical composition of Claim 57 wherein the aqueous medium comprises gastric secretions.

60. (New) The liquid pharmaceutical composition of Claim 57 wherein the aqueous medium comprises water.

61. (New) A liquid pharmaceutical composition produced by the method of combining the dosage form recited in Claim 37 with an aqueous medium.

62. (New) The liquid pharmaceutical composition of Claim 61 wherein the aqueous medium comprises sodium bicarbonate solution.

63. (New) The liquid pharmaceutical composition of Claim 61 wherein the aqueous medium comprises gastric secretions.

64. (New) The liquid pharmaceutical composition of Claim 61 wherein the aqueous medium comprises water.

65. (New) A liquid pharmaceutical composition produced by the method of combining the dosage form recited in Claim 38 with an aqueous medium.

66. (New) The liquid pharmaceutical composition of Claim 65 wherein the aqueous medium comprises sodium bicarbonate solution.

67. (New) The liquid pharmaceutical composition of Claim 65 wherein the aqueous medium comprises gastric secretions.

68. (New) The liquid pharmaceutical composition of Claim 65 wherein the aqueous medium comprises water.

69. (New) A liquid pharmaceutical composition produced by the method of combining the dosage form recited in Claim 39 with an aqueous medium.

70. (New) The liquid pharmaceutical composition of Claim 69 wherein the aqueous medium comprises sodium bicarbonate solution.

71. (New) The liquid pharmaceutical composition of Claim 69 wherein the aqueous medium comprises gastric secretions.

72. (New) The liquid pharmaceutical composition of Claim 69 wherein the aqueous medium comprises water.

73. (New) A liquid pharmaceutical composition produced by the method of combining the dosage form recited in Claim 40 with an aqueous medium.

74. (New) The liquid pharmaceutical composition of Claim 73 wherein the aqueous medium comprises sodium bicarbonate solution.

75. (New) The liquid pharmaceutical composition of Claim 73 wherein the aqueous medium comprises gastric secretions.

76. (New) The liquid pharmaceutical composition of Claim 73 wherein the aqueous medium comprises water.

77. (New) A liquid pharmaceutical composition produced by the method of combining the dosage form recited in Claim 41 with an aqueous medium.

78. (New) The liquid pharmaceutical composition of Claim 77 wherein the aqueous medium comprises sodium bicarbonate solution.

79. (New) The liquid pharmaceutical composition of Claim 77 wherein the aqueous medium comprises gastric secretions.

80. (New) The liquid pharmaceutical composition of Claim 77 wherein the aqueous medium comprises water.

81. (New) A liquid pharmaceutical composition produced by the method of combining the dosage form recited in Claim 42 with an aqueous medium.

82. (New) The liquid pharmaceutical composition of Claim 81 wherein the aqueous medium comprises sodium bicarbonate solution.

83. (New) The liquid pharmaceutical composition of Claim 81 wherein the aqueous medium comprises water.

84. (New) A liquid pharmaceutical composition produced by the method of combining the dosage form recited in Claim 43 with an aqueous medium.

85. (New) The liquid pharmaceutical composition of Claim 84 wherein the aqueous medium comprises sodium bicarbonate solution.

86. (New) The liquid pharmaceutical composition of Claim 84 wherein the aqueous medium comprises water.

87. (New) A liquid pharmaceutical composition produced by the method of combining the dosage form recited in Claim 44 with an aqueous medium.

88. (New) The liquid pharmaceutical composition of Claim 87 wherein the aqueous medium comprises sodium bicarbonate solution.

89. (New) The liquid pharmaceutical composition of Claim 87 wherein the aqueous medium comprises gastric secretions.

90. (New) The liquid pharmaceutical composition of Claim 87 wherein the aqueous medium comprises water.

91. (New) A liquid pharmaceutical composition produced by the method of combining the dosage form recited in Claim 45 with an aqueous medium.

92. (New) The liquid pharmaceutical composition of Claim 91 wherein the aqueous medium comprises sodium bicarbonate solution.

93. (New) The liquid pharmaceutical composition of Claim 91 wherein the aqueous medium comprises gastric secretions.

94. (New) The liquid pharmaceutical composition of Claim 91 wherein the aqueous medium comprises water.

Sub B9
95. (New) A method of treating an acid-related gastrointestinal condition, comprising orally administering to a subject a solid pharmaceutical dosage form that is not enteric-coated or delayed-released, comprising:

(a) a proton pump inhibitor (PPI) selected from a group consisting of omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole and leminoprazole; and

(b) at least one buffering agent present in an amount sufficient to prevent or inhibit acid degradation of the PPI by gastric acid so as to achieve bioavailability of the PPI in the subject after oral administration of the dosage form.

96. (New) The method as recited in Claim 95 wherein the disorder is duodenal ulcer disease.

97. (New) The method as recited in Claim 95 wherein the disorder is a gastric ulcer disease.

98. (New) The method as recited in Claim 95 wherein the disorder is gastroesophageal reflux disease (GERD).

99. (New) The method as recited in Claim 95 wherein the disorder is erosive esophagitis.

100. (New) The method as recited in Claim 95 wherein the disorder is poorly responsive symptomatic GERD.

101. (New) The method as recited in Claim 95 wherein the disorder is a pathological hypersecretory disease.

102. (New) The method as recited in Claim 95 wherein the disorder is Zollinger Ellison Syndrome.

103. (New) The method as recited in Claim 95 wherein the disorder is dyspepsia.

104. (New) The method as recited in Claim 95 wherein the PPI is omeprazole.

105. (New) The method as recited in Claim 95 wherein the PPI is lansoprazole.

106. (New) The method as recited in Claim 95 wherein the PPI is rabeprazole.

107. (New) The method as recited in Claim 95 wherein the PPI is esomeprazole.

108. (New) The method as recited in Claim 95 wherein the PPI is pantoprazole.

109. (New) The method as recited in Claim 95 wherein the PPI is pariprazole.

110. (New) The method as recited in Claim 95 wherein the PPI is leminoprazole.

111. (New) The method as recited in Claim 95 wherein the PPI comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

112. (New) The method as recited in Claim 95 wherein the dosage form further comprises a flavoring agent.

113. (New) The method as recited in Claim 95 wherein the dosage form further comprises an anti-foaming agent.

114. (New) The method as recited in Claim 95 wherein the dosage form is a tablet.
115. (New) The method as recited in Claim 95 wherein the dosage form is a powder.
116. (New) The method as recited in Claim 95 wherein the dosage form is a suspension tablet.
117. (New) The method as recited in Claim 95 wherein the dosage form is a chewable tablet.
118. (New) The method as recited in Claim 117 wherein the dosage form further comprises aspartame.
119. (New) The method as recited in Claim 95 wherein the dosage form is a capsule.
120. (New) The method as recited in Claim 95 wherein the dosage form is an effervescent powder.
121. (New) The method as recited in Claim 95 wherein the dosage form is an effervescent tablet.
122. (New) The method as recited in Claim 95 wherein the dosage form is a plurality of pellets.
123. (New) The method as recited in Claim 95 wherein the dosage form is a plurality of granules.
124. (New) The method as recited in Claim 95 wherein the buffering agent is present in an amount of about 4 mEq to about 30 mEq.

125. (New) The method as recited in Claim 95 wherein the buffering agent is present in an amount of about 7.5 mEq to about 15 mEq.

126. (New) The method as recited in Claim 95 wherein the buffering agent is present in an amount of about 10 mEq to about 20 mEq.

127. (New) The method as recited in Claim 95 wherein the buffering agent comprises a bicarbonate salt of a Group IA metal.

128. (New) The method as recited in Claim 95 wherein the buffering agent comprises at least one of magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium silicate, magnesium lactate, and other magnesium salts.

129. (New) The method as recited in Claim 95 wherein the buffering agent comprises at least one of calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, calcium gluconate, calcium glycinate, calcium maleate, and other calcium salts.

130. (New) The method as recited in Claim 95 wherein the buffering agent comprises about 250 mg to about 1680 mg sodium bicarbonate.

131. (New) The method as recited in Claim 95 wherein the buffering agent comprises about 840 mg to about 1680 mg sodium bicarbonate.

132. (New) The method as recited in Claim 95 wherein the buffering agent comprises about 250 mg to about 1000 mg calcium carbonate.

Sh 10
133. (New) The method as recited in Claim 95 wherein the buffering agent comprises about 500 mg to about 1000 mg calcium carbonate.

134. (New) The method as recited in Claim 95 wherein the buffering agent comprises a combination of sodium bicarbonate and calcium carbonate.

135. (New) The method as recited in Claim 95 further comprising combining the dosage form with an aqueous medium.

136. (New) The method as recited in Claim 135 wherein the aqueous medium comprises sodium bicarbonate solution.

Q,
137. (New) The method as recited in Claim 135 wherein the aqueous medium comprises 8.4% (w/v) sodium bicarbonate solution.

138. (New) The method as recited in Claim 137 wherein the solution is present in an amount of about 10 ml to about 60 ml.

139. (New) The method as recited in Claim 135 wherein the aqueous medium comprises water.

140. (New) The method as recited in Claim 135 wherein the aqueous medium comprises at least one flavoring agent.

Sub B13

141. (New) A composition, comprising:

- (a) a proton pump inhibitor (PPI) selected from a group consisting of omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole and leminoprazole;
- (b) gastric secretions; and
- (c) at least one buffering agent present in an amount sufficient to prevent or inhibit acid degradation of the PPI by the gastric secretions so as to achieve bioavailability of the PPI in a subject,

wherein the PPI and the buffering agent comprise a solid dosage form, which is capable of disintegration and dissolution in the gastric secretions and is not enteric-coated or delayed-released.

R1

142. (New) The composition as recited in Claim 141 wherein the bioavailability of the PPI is sufficient to elicit a therapeutic effect.

143. (New) The composition as recited in Claim 141 wherein the PPI is present in a therapeutically effective amount.

Sub B14

144. The composition as recited in Claim 141 wherein the PPI comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

145. (New) The composition as recited in Claim 141 wherein the PPI is omeprazole.

146. (New) The composition as recited in Claim 141 wherein the PPI is lansoprazole.

147. (New) The composition as recited in Claim 141 wherein the PPI is rabeprazole.
148. (New) The composition as recited in Claim 141 wherein the PPI is esomeprazole.
149. (New) The composition as recited in Claim 141 wherein the PPI is pantoprazole.
150. (New) The composition as recited in Claim 141 wherein the PPI is pariprazole.
151. (New) The composition as recited in Claim 141 wherein the PPI is leminoprazole.
152. (New) The composition as recited in Claim 141 further comprising a flavoring agent.
153. (New) The composition as recited in Claim 141 further comprising an anti-foaming agent.
154. (New) The composition as recited in Claim 141 wherein the dosage form is a tablet.
155. (New) The composition as recited in Claim 141 wherein the dosage form is a powder.
156. (New) The composition as recited in Claim 141 wherein the dosage form is a suspension tablet.
157. (New) The composition as recited in Claim 141 wherein the dosage form is a chewable tablet.
158. (New) The composition as recited in Claim 157 wherein the dosage form further comprises aspartame.

159. (New) The composition as recited in Claim 141 wherein the dosage form is a capsule.

160. (New) The composition as recited in Claim 141 wherein the dosage form is an effervescent powder.

161. (New) The composition as recited in Claim 141 wherein the dosage form is an effervescent tablet.

162. (New) The composition as recited in Claim 141 wherein the dosage form is a plurality of pellets.

163. (New) The composition as recited in Claim 141 wherein the dosage form is a plurality of granules.

164. (New) The composition as recited in Claim 141 wherein the buffering agent is present in an amount of about 4 mEq to about 30 mEq.

165. (New) The composition as recited in Claim 141 wherein the buffering agent is present in an amount of about 7.5 mEq to about 15 mEq.

166. (New) The composition as recited in Claim 141 wherein the buffering agent is present in an amount of about 10 mEq to about 20 mEq.

167. (New) The composition as recited in Claim 141 wherein the buffering agent comprises a bicarbonate salt of a Group IA metal.

168. (New) The composition as recited in Claim 141 wherein the buffering agent comprises at least one of magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium silicate, magnesium lactate and other magnesium salts.

169. (New) The composition as recited in Claim 141 wherein the buffering agent comprises at least one of calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, calcium gluconate, calcium glycinate, calcium maleate, and other calcium salts.

170. (New) The composition as recited in Claim 141 wherein the buffering agent comprises about 250 mg to about 1680 mg sodium bicarbonate.

171. (New) The composition as recited in Claim 141 wherein the buffering agent comprises about 840 mg to about 1680 mg sodium bicarbonate.

172. (New) The composition as recited in Claim 141 wherein the buffering agent comprises about 250 mg to about 1000 mg calcium carbonate.

173. (New) The composition as recited in Claim 141 wherein the buffering agent comprises about 500 mg to about 1000 mg calcium carbonate.

174. (New) The composition as recited in Claim 141 wherein the buffering agent comprises a combination of sodium bicarbonate and calcium carbonate.

175. (New) The composition as recited in Claim 141 further comprising a second aqueous medium.

176. (New) The composition as recited in Claim 175 wherein the second aqueous medium is sodium bicarbonate solution.

177. (New) The composition as recited in Claim 175 wherein the second aqueous medium is 8.4% (w/v) sodium bicarbonate solution.

178. (New) The composition as recited in Claim 176 wherein the sodium bicarbonate solution is present in an amount of about 10 ml to about 60 ml.

179. (New) The composition as recited in Claim 175 wherein the second aqueous medium is water.

180. (New) The composition of Claim 179 wherein the water is present in an amount of about 10 ml to about 60 ml.

181. (New) A solid pharmaceutical dosage form that is not enteric-coated or delayed-released, comprising:

Sub B16

(a) a first part comprising a proton pump inhibitor (PPI) selected from a group consisting of omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole and leminoprazole; and

A1

(b) a second part surrounding the first part, the second part comprising at least one buffering agent present in an amount sufficient to prevent or inhibit acid degradation of the PPI by gastric acid so as to achieve bioavailability of the PPI in a subject after oral administration of the dosage form.

182. (New) The dosage form as recited in Claim 181 wherein the bioavailability of the PPI is sufficient to elicit a therapeutic effect.

183. (New) The dosage form as recited in Claim 181 wherein the PPI is present in a therapeutically effective amount.

Sub B17

184. (New) The dosage form as recited in Claim 181 wherein the PPI comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

185. (New) The dosage form as recited in Claim 181 wherein the PPI is omeprazole.

186. (New) The dosage form as recited in Claim 181 wherein the PPI is lansoprazole.

187. (New) The dosage form as recited in Claim 181 wherein the PPI is rabeprazole.

188. (New) The dosage form as recited in Claim 181 wherein the PPI is esomeprazole.

189. (New) The dosage form as recited in Claim 181 wherein the PPI is pantoprazole.
190. (New) The dosage form as recited in Claim 181 wherein the PPI is pariprazole.
191. (New) The dosage form as recited in Claim 181 wherein the PPI is leminoprazole.
192. (New) The dosage form as recited in Claim 181 wherein the first part comprises a compressed tablet.
193. (New) The dosage form as recited in Claim 192 wherein the second part further comprises a capsule which surrounds the buffering agent and the tablet.
194. (New) The dosage form as recited in Claim 181 wherein the first part further comprises a capsule containing the PPI, and the second part further comprises a capsule containing the capsule of the first part.
195. (New) The dosage form as recited in Claim 181 wherein the buffering agent comprises a bicarbonate salt of a Group IA metal.
196. (New) The dosage form as recited in Claim 181 wherein the buffering agent comprises at least one of magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium silicate, magnesium lactate and other magnesium salts. *Mg CO₃ in 24*
197. (New) The dosage form as recited in Claim 181 wherein the buffering agent comprises at least one of calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, calcium gluconate, calcium glycinate, calcium maleate, and other calcium salts.

Sub B18
198. (New) The dosage form as recited in Claim 181 wherein the buffering agent is about 250 mg to about 1680 mg sodium bicarbonate.

199. (New) The dosage form as recited in Claim 181 wherein the buffering agent is about 840 mg to about 1680 mg sodium bicarbonate.

200. (New) The dosage form as recited in Claim 181 wherein the buffering agent comprises about 250 mg to about 1000 mg calcium carbonate.

Q1
201. (New) The dosage form as recited in Claim 181 wherein the buffering agent comprises about 500 mg to about 1000 mg calcium carbonate.

202. (New) The dosage form as recited in Claim 181 wherein the buffering agent comprises a combination of sodium bicarbonate and calcium carbonate.

203. (New) A method of treating an acid-related gastrointestinal condition, comprising orally administering to a subject a solid pharmaceutical dosage form that is not enteric-coated or delayed-released, comprising:

(a) a first part comprising a proton pump inhibitor (PPI) selected from a group consisting of omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole and leminoprazole; and

(b) a second part surrounding the first part, the second part comprising at least one buffering agent present in an amount sufficient to prevent or inhibit acid degradation of the PPI by gastric acid so as to achieve bioavailability of the PPI in the subject after oral administration of the dosage form.

204. (New) The method as recited in Claim 203 wherein the disorder is duodenal ulcer disease.

205. (New) The method as recited in Claim 203 wherein the disorder is a gastric ulcer disease.

206. (New) The method as recited in Claim 203 wherein the disorder is gastroesophageal reflux disease (GERD).

207. (New) The method as recited in Claim 203 wherein the disorder is erosive esophagitis.

208. (New) The method as recited in Claim 203 wherein the disorder is poorly responsive symptomatic GERD.

209. (New) The method as recited in Claim 203 wherein the disorder is a pathological hypersecretory disease.

210. (New) The method as recited in Claim 203 wherein the disorder is Zollinger Ellison Syndrome.

211. (New) The method as recited in Claim 203 wherein the disorder is dyspepsia.

212. (New) The method as recited in Claim 203 wherein the PPI is omeprazole.

213. (New) The method as recited in Claim 203 wherein the PPI is lansoprazole.

214. (New) The method as recited in Claim 203 wherein the PPI is rabeprazole.

215. (New) The method as recited in Claim 203 wherein the PPI is esomeprazole.

216. (New) The method as recited in Claim 203 wherein the PPI is pantoprazole.

217. (New) The method as recited in Claim 203 wherein the PPI is pariprazole.

218. (New) The method as recited in Claim 203 wherein the PPI is leminoprazole.

219. (New) The method as recited in Claim 203 wherein the PPI comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

220. (New) The method as recited in Claim 203 wherein the first part comprises a compressed tablet.

221. (New) The method as recited in Claim 220 wherein the second part further comprises a capsule which surrounds the buffering agent and the tablet.

222. (New) The method as recited in Claim 203 wherein the first part further comprises a capsule containing the PPI, and the second part further comprises a capsule containing the capsule of the first part.

223. (New) The method as recited in Claim 203 wherein the buffering agent is present in an amount of about 4 mEq to about 30 mEq.

224. (New) The method as recited in Claim 203 wherein the buffering agent is present in an amount of about 7.5 mEq to 15 mEq.

225. (New) The method as recited in Claim 203 wherein the buffering agent is present in an amount of about 10 mEq to about 20 mEq.

226. (New) The method as recited in Claim 203 wherein the buffering agent comprises a bicarbonate salt of a Group IA metal.

227. (New) The method as recited in Claim 203 wherein the buffering agent comprises at least one of magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium silicate, magnesium lactate, and other magnesium salts.

228. (New) The method as recited in Claim 203 wherein the buffering agent comprises at least one of calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, calcium gluconate, calcium glycinate, calcium maleate, and other calcium salts.

Sub B21
229. (New) The method as recited in Claim 203 wherein the buffering agent comprises about 250 mg to about 1680 mg sodium bicarbonate.

230. (New) The method as recited in Claim 203 wherein the buffering agent comprises about 840 mg to about 1680 mg sodium bicarbonate.

231. (New) The method as recited in Claim 203 wherein the buffering agent comprises about 500 to about 1000 mg calcium carbonate.

232. (New) The method as recited in Claim 203 wherein the buffering agent comprises about 250 mg to about 1000 mg calcium carbonate.

Sub B22
233. (New) The method as recited in Claim 203 wherein the buffering agent comprises a combination of sodium bicarbonate and calcium bicarbonate.

234. (New) The method as recited in Claim 203 further comprising combining the dosage form with an aqueous medium prior to administration.

235. (New) The method as recited in Claim 234 wherein the aqueous medium comprises sodium bicarbonate solution.

236. (New) The method as recited in Claim 234 wherein the aqueous medium comprises 8.4% (w/v) sodium bicarbonate solution.

237. (New) The method as recited in Claim 234 wherein the aqueous medium comprises water.

238. (New) A solid pharmaceutical dosage form, comprising:

(a) a first part comprising a proton pump inhibitor (PPI) that is in an enteric-coated or delayed-released form, the PPI selected from a group consisting of omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole and leminoprazole; and

(b) a second part contacting the first part, the second part comprising at least one buffering agent present in an amount of about 4 mEq to about 30 mEq.

239. (New) The dosage form as recited in Claim 238 wherein the buffering agent is present in an amount of about 7.5 mEq to about 15 mEq.

240. (New) The dosage form as recited in Claim 238 wherein the buffering agent is present in an amount of about 10 mEq to about 20 mEq.

241. (New) The dosage form as recited in Claim 238 wherein the bioavailability of the PPI is sufficient to elicit a therapeutic effect.

242. (New) The dosage form as recited in Claim 238 wherein the PPI is present in a therapeutically effective amount.

243. (New) The dosage form as recited in Claim 238 wherein the PPI comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

244. (New) The dosage form as recited in Claim 238 wherein the PPI is omeprazole.

245. (New) The dosage form as recited in Claim 238 wherein the PPI is lansoprazole.

246. (New) The dosage form as recited in Claim 238 wherein the PPI is rabeprazole.

247. (New) The dosage form as recited in Claim 238 wherein the PPI is esomeprazole.
248. (New) The dosage form as recited in Claim 238 wherein the PPI is pantoprazole.
249. (New) The dosage form as recited in Claim 238 wherein the PPI is pariprazole.
250. (New) The dosage form as recited in Claim 238 wherein the PPI is leminoprazole.
251. (New) The dosage form as recited in Claim 238 wherein the PPI comprises enteric coated granules, which surround an inner core of the second part, the second part further comprising a non-enteric-coated PPI.
252. (New) The dosage form as recited in Claim 238 wherein the first part further comprises a non-enteric-coated PPI.
253. (New) The dosage form as recited in Claim 238 wherein the first part further comprises a non-enteric-coated PPI and the second part surrounds the first part.
254. (New) The dosage form as recited in Claim 238 wherein the first part is a tablet.
255. (New) The dosage form as recited in Claim 254 wherein the second part further comprises a capsule which surrounds the buffering agent and the tablet.
256. (New) The dosage form as recited in Claim 238 wherein the first part further comprises a capsule containing the PPI, and the second part further comprises a capsule containing the capsule of the first part.
257. (New) The dosage form as recited in Claim 238 wherein the buffering agent comprises a bicarbonate salt of a Group IA metal.

258. (New) The dosage form as recited in Claim 238 wherein the buffering agent comprises at least one of magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium silicate, magnesium lactate and other magnesium salts.

259. (New) The dosage form as recited in Claim 238 wherein the buffering agent comprises at least one of calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, calcium gluconate, calcium glycinate, calcium maleate, and other calcium salts.

260. (New) The dosage form as recited in Claim 238 wherein the buffering agent comprises about 250 mg to about 1680 mg sodium bicarbonate.

261. (New) The dosage form as recited in Claim 238 wherein the buffering agent comprises about 840 mg to about 1680 mg sodium bicarbonate.

262. (New) The dosage form as recited in Claim 238 wherein the buffering agent comprises about 250 mg to about 1000 mg calcium carbonate.

263. The dosage form as recited in Claim 238 wherein the buffering agent comprises about 500 mg to about 1000 mg calcium carbonate.

264. (New) The dosage form as recited in Claim 238 wherein the buffering agent comprises a combination of sodium bicarbonate and calcium carbonate.

265. (New) The dosage form as recited in Claim 238 wherein the second part surrounds the first part and wherein the second part further comprises non-enteric-coated PPI.

266. (New) A method of treating an acid-related gastrointestinal condition, comprising orally administering to a subject a solid pharmaceutical dosage form, comprising:

(a) a first part comprising a proton pump inhibitor (PPI) that is in an enteric-coated or delayed-released form, the PPI selected from a group consisting of omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole and leminoprazole; and

(b) a second part contacting the first part, the second part comprising at least one buffering agent present in an amount of about 4 mEq to about 30 mEq.

267. (New) The method as recited in Claim 266 wherein the buffering agent is present in an amount of about 7.5 mEq to about 15 mEq.

268. (New) The method as recited in Claim 266 wherein the buffering agent is present in an amount of about 10 mEq to about 20 mEq.

269. (New) The method as recited in Claim 266 wherein the PPI comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

270. (New) The method as recited in Claim 266 wherein the PPI is omeprazole.

271. (New) The method as recited in Claim 266 wherein the PPI is lansoprazole.

272. (New) The method as recited in Claim 266 wherein the PPI is rabeprazole.

273. (New) The method as recited in Claim 266 wherein the PPI is esomeprazole.

274. (New) The method as recited in Claim 266 wherein the PPI is pantoprazole.

275. (New) The method as recited in Claim 266 wherein the PPI is pariprazole.

276. (New) The method as recited in Claim 266 wherein the PPI is leminoprazole.
277. (New) The method as recited in Claim 266 wherein the PPI comprises enteric coated granules, which surround an inner core of the second part, the second part further comprising a non-enteric-coated PPI.
278. (New) The method as recited in Claim 266 wherein the first part further comprises a non-enteric-coated PPI.
279. (New) The method as recited in Claim 266 wherein the first part further comprises a non-enteric-coated PPI and the second part surrounds the first part.
280. (New) The method as recited in Claim 266 wherein the first part is a tablet.
281. (New) The method as recited in Claim 280 wherein the second part further comprises a capsule which surrounds the buffering agent and the tablet.
282. (New) The method as recited in Claim 266 wherein the first part further comprises a capsule containing the PPI, and the second part further comprises a capsule containing the capsule of the first part.
283. (New) The method as recited in Claim 266 wherein the buffering agent comprises a bicarbonate salt of a Group IA metal.
284. (New) The method as recited in Claim 266 wherein the buffering agent comprises at least one of magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium silicate, magnesium lactate, and other magnesium salts.

285. (New) The method as recited in Claim 266 wherein the buffering agent comprises at least one of calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, calcium gluconate, calcium glycinate, calcium maleate, and other calcium salts.

286. (New) The method as recited in Claim 266 wherein the buffering agent comprises about 250 mg to about 1680 mg sodium bicarbonate.

287. (New) The method as recited in Claim 266 wherein the buffering agent comprises about 840 mg to about 1680 mg sodium bicarbonate.

288. (New) The method as recited in Claim 266 wherein the buffering agent comprises about 250 mg to about 1000 mg calcium carbonate.

289. The method as recited in Claim 266 wherein the buffering agent comprises about 500 mg to about 1000 mg calcium carbonate.

290. (New) The method as recited in Claim 266 wherein the buffering agent comprises a combination of sodium bicarbonate and calcium carbonate.

291. (New) The method as recited in Claim 266 wherein the second part surrounds the first part and wherein the second part further comprises non-enteric-coated PPI.

292. (New) A solid pharmaceutical composition, comprising:
- (a) omeprazole; and
 - (b) at least one buffering agent that is not an amino acid, wherein the buffering agent is present in an amount of at least 30 parts to 1 part omeprazole.
293. (New) The composition as recited in Claim 292 wherein the omeprazole comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base salt thereof.
294. (New) The composition as recited in Claim 292 wherein the buffering agent comprises a bicarbonate salt of a Group IA metal.
295. (New) The composition as recited in Claim 292 wherein the buffering agent comprises at least one of magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium silicate, magnesium lactate, and other magnesium salts.
296. (New) The composition as recited in Claim 292 wherein the buffering agent comprises at least one of calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, calcium gluconate, calcium glycinate, calcium maleate, and other calcium salts.
297. (New) The composition as recited in Claim 292 wherein the buffering agent comprises a combination of sodium bicarbonate and calcium carbonate.
298. (New) The composition as recited in Claim 292 further comprising a flavoring agent.

299. (New) The composition as recited in Claim 292 further comprising an anti-foaming agent.

Al

[Large handwritten signature]

300. (New) A solid pharmaceutical dosage form that is not enteric-coated or delayed-released, comprising:

- (a) omeprazole; and
- (b) at least one buffering agent present in an amount sufficient to prevent or inhibit acid degradation of the omeprazole by gastric acid so as to achieve bioavailability of the omeprazole in a subject after oral administration of the dosage form.

301. (New) The dosage form as recited in Claim 300 wherein the omeprazole comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

302. (New) The dosage form as recited in Claim 300 further comprising a flavoring agent.

303. (New) The dosage form as recited in Claim 300 further comprising an anti-foaming agent.

304. (New) The dosage form as recited in Claim 300 wherein the omeprazole is present in a therapeutically effective amount.

305. (New) The dosage form as recited in Claim 300 wherein the omeprazole is present in an amount of about 10 mg to about 40 mg.

306. (New) The dosage form as recited in Claim 300 wherein the dosage form is a tablet.

307. (New) The dosage form as recited in Claim 300 wherein the dosage form is a powder.

308. (New) The dosage form as recited in Claim 300 wherein the dosage form is a suspension tablet.

309. (New) The dosage form as recited in Claim 300 wherein the dosage form is a chewable tablet.

310. (New) The dosage form as recited in Claim 309 further comprising aspartame.

311. (New) The dosage form as recited in Claim 300 wherein the dosage form is a capsule.

312. (New) The dosage form as recited in Claim 300 wherein the dosage form is an effervescent powder.

313. (New) The dosage form as recited in Claim 300 wherein the dosage form is an effervescent tablet.

314. (New) The dosage form as recited in Claim 300 wherein the dosage form is a plurality of pellets.

315. (New) The dosage form as recited in Claim 300 wherein the dosage form is a plurality of granules.

316. (New) The dosage form as recited in Claim 300 wherein the buffering agent is present in an amount of about 4 mEq to about 30 mEq.

317. (New) The dosage form as recited in Claim 300 wherein the buffering agent is present in an amount of about 7.5 mEq to about 15 mEq.

318. (New) The dosage form as recited in Claim 300 wherein the buffering agent is present in an amount of about 10 mEq to about 20 mEq.

319. (New) The dosage form as recited in Claim 300 wherein the buffering agent comprises a bicarbonate salt of a Group IA metal.

320. (New) The dosage form as recited in Claim 300 wherein the buffering agent comprises sodium bicarbonate.

321. (New) The dosage form as recited in Claim 300 wherein the buffering agent comprises about 250 mg to about 1680 mg sodium bicarbonate.

322. (New) The dosage form as recited in Claim 300 wherein the buffering agent comprises about 840 mg to about 1680 mg sodium bicarbonate.

323. (New) The dosage form as recited in Claim 300 wherein the buffering agent comprises calcium carbonate.

324. (New) The dosage form as recited in Claim 300 wherein the buffering agent comprises about 250 mg to about 1000 mg calcium carbonate.

325. (New) The dosage form as recited in Claim 300 wherein the buffering agent comprises about 500 mg to about 1000 mg calcium carbonate.

326. (New) The dosage form as recited in Claim 300 wherein the buffering agent comprises a combination of calcium carbonate and sodium bicarbonate.

327. (New) The dosage form as recited in Claim 300 wherein the buffering agent comprises at least one of magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium silicate, magnesium lactate and other magnesium salts.

328. (New) The dosage form as recited in Claim 302 wherein the buffering agent comprises at least one of calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, calcium gluconate, calcium glycinate, calcium maleate, and other calcium salts.

a,
329. (New) A liquid pharmaceutical composition produced by the method of combining the dosage form recited in Claim 300 with an aqueous medium.


330. (New) The liquid pharmaceutical composition of Claim 329 wherein the aqueous medium comprises sodium bicarbonate solution.

331. (New) The liquid pharmaceutical composition of Claim 329 wherein the aqueous medium comprises gastric secretions.

332. (New) The liquid pharmaceutical composition of Claim 329 wherein the aqueous medium comprises water.

333. (New) The liquid pharmaceutical composition as recited in Claim 329 wherein the dosage form is a powder and the aqueous medium is water.

334. (New) The liquid pharmaceutical composition as recited in Claim 329 wherein the dosage form is a plurality of granules and the aqueous medium is water.



A/

335. (New) A method of treating an acid-related gastrointestinal condition, comprising orally administering to a subject a solid pharmaceutical dosage form to a subject that is not enteric-coated or delayed-released, comprising:

- (a) omeprazole; and
- (b) at least one buffering agent present in an amount sufficient to prevent or inhibit acid degradation of the omeprazole by gastric acid so as to achieve bioavailability of the omeprazole in the subject after oral administration of the dosage form.

336. (New) The method as recited in Claim 335 wherein the disorder is duodenal ulcer disease.

337. (New) The method as recited in Claim 335 wherein the disorder is a gastric ulcer disease.

338. (New) The method as recited in Claim 335 wherein the disorder is gastroesophageal reflux disease (GERD).

339. (New) The method as recited in Claim 335 wherein the disorder is erosive esophagitis.

340. (New) The method as recited in Claim 335 wherein the disorder is poorly responsive symptomatic GERD.

341. (New) The method as recited in Claim 335 wherein the disorder is a pathological hypersecretory disease.

342. (New) The method as recited in Claim 335 wherein the disorder is Zollinger Ellison Syndrome.

343. (New) The method as recited in Claim 335 wherein the disorder is dyspepsia.

344. (New) The method as recited in Claim 335 wherein the omeprazole comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

345. (New) The method as recited in Claim 335 wherein the dosage form further comprises a flavoring agent.

346. (New) The method as recited in Claim 335 wherein the dosage form further comprises an anti-foaming agent.

347. (New) The method as recited in Claim 335 wherein the omeprazole is present in an amount of about 10 mg to about 40 mg.

348. (New) The method as recited in Claim 335 wherein the dosage form is a tablet.

349. (New) The method as recited in Claim 335 wherein the dosage form is a powder.

350. (New) The method as recited in Claim 335 wherein the dosage form is a suspension tablet.

351. (New) The method as recited in Claim 335 wherein the dosage form is a chewable tablet.

352. (New) The method as recited in Claim 351 wherein the chewable table further comprises aspartame.

353. (New) The method as recited in Claim 335 wherein the dosage form is a capsule.
354. (New) The method as recited in Claim 335 wherein the dosage form is an effervescent powder.
355. (New) The method as recited in Claim 335 wherein the dosage form is an effervescent tablet.
356. (New) The method as recited in Claim 335 wherein the dosage form is a plurality of pellets.
357. (New) The method as recited in Claim 335 wherein the dosage form is a plurality of granules.
358. (New) The method as recited in Claim 335 wherein the buffering agent is present in an amount of about 4 mEq to about 30 mEq.
359. (New) The method as recited in Claim 335 wherein the buffering agent is present in an amount of about 7.5 mEq to about 15 mEq.
360. (New) The method as recited in Claim 335 wherein the buffering agent is present in an amount of about 10 mEq to about 20 mEq.
361. (New) The method as recited in Claim 335 wherein the buffering agent comprises a bicarbonate salt of a Group IA metal.
362. (New) The method as recited in Claim 335 wherein the buffering agent comprises sodium bicarbonate.

363. (New) The method as recited in Claim 335 wherein the buffering agent comprises about 250 mg to about 1680 mg sodium bicarbonate.

364. (New) The method as recited in Claim 335 wherein the buffering agent comprises about 840 mg to about 1680 mg sodium bicarbonate.

365. (New) The method as recited in Claim 335 wherein the buffering agent comprises calcium carbonate.

366. (New) The method as recited in Claim 335 wherein the buffering agent comprises about 250 mg to about 1000 mg calcium carbonate.

367. (New) The method as recited in Claim 335 wherein the buffering agent comprises about 500 mg to about 1000 mg calcium carbonate.

368. (New) The method as recited in Claim 335 wherein the buffering agent comprises a combination of calcium carbonate and sodium bicarbonate.

369. (New) The method as recited in Claim 335 wherein the buffering agent comprises at least one of magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium silicate, magnesium lactate and other magnesium salts.

370. (New) The method as recited in Claim 335 wherein the buffering agent comprises at least one of calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, calcium gluconate, calcium glycinate, calcium maleate, and other calcium salts.

371. (New) A composition, comprising:

- (a) omeprazole;
- (b) gastric secretions; and
- (c) at least one buffering agent present in an amount sufficient to prevent or inhibit acid degradation of the omeprazole by the gastric secretions so as to achieve bioavailability of the omeprazole in a subject,

wherein the omeprazole and the buffering agent comprise a solid dosage form, which is capable of disintegration and dissolution in the gastric secretions and is not enteric-coated or delayed-released.

372. (New) The composition as recited in Claim 371 wherein the omeprazole comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

373. (New) The composition as recited in Claim 371 wherein the omeprazole is present in a therapeutically effective amount.

374. (New) The composition as recited in Claim 371 wherein the omeprazole is present in an amount of about 10 mg to about 40 mg.

375. (New) The composition as recited in Claim 371 wherein the dosage form is a tablet.

376. (New) The composition as recited in Claim 371 wherein the dosage form is a powder.

377. (New) The composition as recited in Claim 371 wherein the dosage form is a suspension tablet.

378. (New) The composition as recited in Claim 371 wherein the dosage form is a chewable tablet.

379. (New) The composition as recited in Claim 378 wherein the chewable tablet further comprises aspartame.

380. (New) The composition as recited in Claim 371 wherein the dosage form is a capsule.

381. (New) The composition as recited in Claim 371 wherein the dosage form is an effervescent powder.

382. (New) The composition as recited in Claim 371 wherein the dosage form is an effervescent tablet.

383. (New) The composition as recited in Claim 371 wherein the dosage form is a plurality of pellets.

384. (New) The composition as recited in Claim 371 wherein the dosage form is a plurality of granules.

385. (New) The composition as recited in Claim 371 wherein the buffering agent is present in an amount of about 4 mEq to about 30 mEq.

386. (New) The composition as recited in Claim 371 wherein the buffering agent is present in an amount of about 7.5 mEq to about 15 mEq.

387. (New) The composition as recited in Claim 371 wherein the buffering agent is present in an amount of about 10 mEq to about 20 mEq.

388. (New) The composition as recited in Claim 371 wherein the buffering agent comprises sodium bicarbonate.

389. (New) The composition as recited in Claim 371 wherein the buffering agent comprises about 250 mg to about 1680 mg sodium bicarbonate.

390. (New) The composition as recited in Claim 371 wherein the buffering agent comprises about 840 mg to about 1680 mg sodium bicarbonate.

391. (New) The composition as recited in Claim 371 wherein the buffering agent comprises calcium carbonate.

392. (New) The composition as recited in Claim 371 wherein the buffering agent comprises about 250 mg to about 1000 mg calcium carbonate.

393. (New) The composition as recited in Claim 371 wherein the buffering agent comprises about 500 mg to about 1000 mg calcium carbonate.

394. (New) The composition as recited in Claim 371 wherein the buffering agent comprises a combination of calcium carbonate and sodium bicarbonate.

395. (New) The composition as recited in Claim 371 wherein the buffering agent comprises at least one of magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium silicate, magnesium lactate and other magnesium salts.

396. (New) The composition as recited in Claim 371 wherein the buffering agent comprises at least one of calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, calcium gluconate, calcium glycinate, calcium maleate, and other calcium salts.

397. (New) The composition as recited in Claim 371 further comprising a flavoring agent.

398. (New) The composition as recited in Claim 371 further comprising an anti-foaming agent.

399. (New) A solid pharmaceutical dosage form that is not enteric-coated or delayed-released, comprising:

- (a) a first part comprising omeprazole; and
- (b) a second part surrounding the first part, the second part comprising at least one buffering agent present in an amount sufficient to prevent or inhibit acid degradation of the omeprazole by gastric acid so as to achieve bioavailability of the omeprazole in a subject after oral administration of the dosage form.

400. (New) The dosage form as recited in Claim 399 wherein the bioavailability of the omeprazole is sufficient to elicit a therapeutic effect.

401. (New) The dosage form as recited in Claim 399 wherein the omeprazole is present in a therapeutically effective amount.

402. (New) The dosage form as recited in Claim 399 wherein the omeprazole comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

403. (New) The dosage form as recited in Claim 399 wherein the first part comprises a compressed tablet.

404. (New) The dosage form as recited in Claim 403 wherein the second part further comprises a capsule which surrounds the buffering agent and the tablet.

405. (New) The dosage form as recited in Claim 399 wherein the first part further comprises a capsule containing the omeprazole and the second part further comprises a capsule containing the capsule of the first part.

406. (New) The dosage form as recited in Claim 399 wherein the buffering agent comprises a bicarbonate salt of a Group IA metal.

407. (New) The dosage form as recited in Claim 399 wherein the buffering agent comprises at least one of magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium silicate, magnesium lactate and other magnesium salts.

408. (New) The dosage form as recited in Claim 399 wherein the buffering agent comprises at least one of calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, calcium gluconate, calcium glycinate, calcium maleate, and other calcium salts.

409. (New) The dosage form as recited in Claim 399 wherein the buffering agent is about 250 mg to about 1680 mg sodium bicarbonate.

410. (New) The dosage form as recited in Claim 399 wherein the buffering agent is about 840 mg to about 1680 mg sodium bicarbonate.

411. (New) The dosage form as recited in Claim 399 wherein the buffering agent comprises about 250 mg to about 1000 mg calcium carbonate.

412. (New) The dosage form as recited in Claim 399 wherein the buffering agent is about 500 mg to about 100 mg calcium carbonate.

413. (New) The dosage form as recited in Claim 399 wherein the buffering agent comprises a combination of sodium bicarbonate and calcium carbonate.

Q1

414. (New) A method of treating an acid-related gastrointestinal condition, comprising orally administering to a subject a solid pharmaceutical dosage form that is not enteric-coated or delayed-released, comprising:

- (a) a first part comprising omeprazole; and
- (b) a second part surrounding the first part, the second part comprising at least one buffering agent present in an amount sufficient to prevent or inhibit acid degradation of the omeprazole by gastric acid so as to achieve bioavailability of the omeprazole in the subject after oral administration of the dosage form.

415. (New) The method as recited in Claim 414 wherein the disorder is duodenal ulcer disease.

416. (New) The method as recited in Claim 414 wherein the disorder is a gastric ulcer disease.

417. (New) The method as recited in Claim 414 wherein the disorder is gastroesophageal reflux disease (GERD).

418. (New) The method as recited in Claim 414 wherein the disorder is erosive esophagitis.

419. (New) The method as recited in Claim 414 wherein the disorder is poorly responsive symptomatic GERD.

420. (New) The method as recited in Claim 414 wherein the disorder is a pathological hypersecretory disease.

421. (New) The method as recited in Claim 414 wherein the disorder is Zollinger Ellison Syndrome.

422. (New) The method as recited in Claim 414 wherein the disorder is dyspepsia.

423. (New) The method as recited in Claim 414 wherein the omeprazole comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

424. (New) The method as recited in Claim 414 wherein the first part comprises a compressed tablet.

425. (New) The method as recited in Claim 424 wherein the second part further comprises a capsule which comprises the buffering agent and the tablet.

426. (New) The method as recited in Claim 414 wherein the first part further comprises a capsule containing the omeprazole, and the second part further comprises a capsule containing the capsule of the first part.

427. (New) The method as recited in Claim 414 wherein the buffering agent is present in an amount of about 4 mEq to about 30 mEq.

428. (New) The method as recited in Claim 414 wherein the buffering agent is present in an amount of about 7.5 mEq to 15 mEq.

429. (New) The method as recited in Claim 414 wherein the buffering agent is present in an amount of about 10 mEq to about 20 mEq.

430. (New) A solid pharmaceutical dosage form, comprising:
- (a) a first part comprising omeprazole that is in an enteric-coated or delayed-released form; and
 - (b) a second part contacting the first part, the second part comprising at least one buffering agent present in an amount of about 4 mEq to about 30 mEq.
431. (New) The dosage form as recited in Claim 430 wherein the buffering agent is present in an amount of about 7.5 mEq to about 15 mEq.
432. (New) The dosage form as recited in Claim 430 wherein the buffering agent is present in an amount of about 10 mEq to about 20 mEq.
433. (New) The dosage form as recited in Claim 430 wherein the bioavailability of the omeprazole is sufficient to elicit a therapeutic effect.
434. (New) The dosage form as recited in Claim 430 wherein the omeprazole is present in a therapeutically effective amount.
435. (New) The dosage form as recited in Claim 430 wherein the omeprazole comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.
436. (New) The dosage form as recited in Claim 430 wherein the omeprazole comprises enteric coated granules, which surround an inner core of the second part, the second part further comprising a non-enteric-coated omeprazole.

437. (New) The dosage form as recited in Claim 430 wherein the first part further comprises a non-enteric-coated omeprazole.

438. (New) The dosage form as recited in Claim 430 wherein the first part further comprises a non-enteric-coated omeprazole and the second part surrounds the first part.

439. (New) The dosage form as recited in Claim 430 wherein the first part is a tablet.

440. (New) The dosage form as recited in Claim 439 wherein the second part further comprises a capsule which surrounds the buffering agent and the tablet.

441. (New) The dosage form as recited in Claim 430 wherein the first part further comprises a capsule containing the omeprazole, and the second part further comprises a capsule containing the capsule of the first part.

442. (New) The dosage form as recited in Claim 430 wherein the buffering agent comprises about 250 mg to about 1680 mg sodium bicarbonate.

443. (New) The dosage form as recited in Claim 430 wherein the buffering agent comprises about 840 mg to about 1680 mg sodium bicarbonate.

444. (New) The dosage form as recited in Claim 430 wherein the buffering agent comprises about 250 mg to about 1000 mg calcium carbonate.

445. The dosage form as recited in Claim 430 wherein the buffering agent comprises about 500 mg to about 1000 mg calcium carbonate.

446. (New) The dosage form as recited in Claim 430 wherein the buffering agent comprises a combination of sodium bicarbonate and calcium carbonate.

447. (New) The dosage form as recited in Claim 430 wherein the buffering agent comprises at least one of magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium silicate, magnesium lactate and other magnesium salts.

448. (New) The dosage form as recited in Claim 430 wherein the buffering agent comprises at least one of calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, calcium gluconate, calcium glycinate, calcium maleate, and other calcium salts.

449. (New) The dosage form as recited in Claim 430 wherein the second part surrounds the first part and wherein the second part further comprises non-enteric-coated omeprazole.

450. (New) A method of treating an acid-related gastrointestinal condition, comprising orally administering to a subject a solid pharmaceutical dosage form, comprising:

(a) a first part comprising omeprazole that is in an enteric-coated or delayed-released form; and

(b) a second part contacting the first part, the second part comprising at least one buffering agent present in an amount of about 4 mEq to about 30 mEq.

451. (New) The method as recited in Claim 450 wherein the buffering agent is present in an amount of about 7.5 mEq to about 15 mEq.

452. (New) The method as recited in Claim 450 wherein the buffering agent is present in an amount of about 10 mEq to about 20 mEq.

453. (New) The method as recited in Claim 450 wherein the omeprazole comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

454. (New) The method as recited in Claim 450 wherein the omeprazole comprises enteric coated granules, which surround an inner core of the second part, the second part further comprising a non-enteric-coated omeprazole.

455. (New) The method as recited in Claim 450 wherein the first part further comprises a non-enteric-coated omeprazole.

456. (New) The method as recited in Claim 450 wherein the first part further comprises a non-enteric-coated omeprazole and the second part surrounds the first part.

457. (New) The method as recited in Claim 450 wherein the first part is a tablet.

458. (New) The method as recited in Claim 457 wherein the second part further comprises a capsule which surrounds the buffering agent and the tablet.

459. (New) The method as recited in Claim 450 wherein the first part further comprises a capsule containing the omeprazole, and the second part further comprises a capsule containing the capsule of the first part.

460. (New) The method as recited in Claim 450 wherein the second part surrounds the first part and wherein the second part further comprises non-enteric-coated omeprazole.

461. (New) A solid pharmaceutical dosage form that is not enteric-coated or delayed-released, comprising:

- (a) lansoprazole; and
- (b) at least one buffering agent present in an amount sufficient to prevent or inhibit acid degradation of the lansoprazole by gastric acid so as to achieve bioavailability of the lansoprazole in a subject after oral administration of the dosage form.

462. (New) The dosage form as recited in Claim 461 wherein the lansoprazole comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

463. (New) The dosage form as recited in Claim 461 further comprising a flavoring agent.

464. (New) The dosage form as recited in Claim 461 further comprising an anti-foaming agent.

465. (New) The dosage form as recited in Claim 461 wherein the lansoprazole is present in a therapeutically effective amount.

466. (New) The dosage form as recited in Claim 461 wherein the lansoprazole is present in an amount of about 10 mg to about 60 mg.

467. (New) The dosage form as recited in Claim 461 wherein the dosage form is a tablet.

468. (New) The dosage form as recited in Claim 461 wherein the dosage form is a powder.

469. (New) The dosage form as recited in Claim 461 wherein the dosage form is a suspension tablet.

470. (New) The dosage form as recited in Claim 461 wherein the dosage form is a chewable tablet.

471. (New) The dosage form as recited in Claim 470 further comprising aspartame.

472. (New) The dosage form as recited in Claim 461 wherein the dosage form is a capsule.

473. (New) The dosage form as recited in Claim 461 wherein the dosage form is an effervescent powder.

474. (New) The dosage form as recited in Claim 461 wherein the dosage form is an effervescent tablet.

475. (New) The dosage form as recited in Claim 461 wherein the dosage form is a plurality of pellets.

476. (New) The dosage form as recited in Claim 461 wherein the dosage form is a plurality of granules.

477. (New) The dosage form as recited in Claim 461 wherein the buffering agent is present in an amount of about 4 mEq to about 30 mEq.

478. (New) The dosage form as recited in Claim 461 wherein the buffering agent is present in an amount of about 7.5 mEq to about 15 mEq.

479. (New) The dosage form as recited in Claim 461 wherein the buffering agent is present in an amount of about 10 mEq to about 20 mEq.

480. (New) The dosage form as recited in Claim 461 wherein the buffering agent comprises a bicarbonate salt of a Group IA metal.

481. (New) The dosage form as recited in Claim 461 wherein the buffering agent comprises sodium bicarbonate.

482. (New) The dosage form as recited in Claim 461 wherein the buffering agent comprises about 250 mg to about 1680 mg sodium bicarbonate.

483. (New) The dosage form as recited in Claim 461 wherein the buffering agent comprises about 840 mg to about 1680 mg sodium bicarbonate.

484. (New) The dosage form as recited in Claim 461 wherein the buffering agent comprises calcium carbonate.

485. (New) The dosage form as recited in Claim 461 wherein the buffering agent comprises about 250 mg to about 1000 mg calcium carbonate.

486. (New) The dosage form as recited in Claim 461 wherein the buffering agent comprises about 500 mg to about 1000 mg calcium carbonate.

487. (New) The dosage form as recited in Claim 461 wherein the buffering agent comprises a combination of calcium carbonate and sodium bicarbonate.

488. (New) The dosage form as recited in Claim 461 wherein the buffering agent comprises at least one of magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium silicate, magnesium lactate and other magnesium salts.

489. (New) The dosage form as recited in Claim 461 wherein the buffering agent comprises at least one of calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, calcium gluconate, calcium glycinate, calcium maleate, and other calcium salts.

490. (New) A liquid pharmaceutical composition produced by the method of combining the dosage form recited in Claim 461 with an aqueous medium.


491. (New) The liquid pharmaceutical composition of Claim 490 wherein the aqueous medium comprises sodium bicarbonate solution.

492. (New) The liquid pharmaceutical composition of Claim 490 wherein the aqueous medium comprises gastric secretions.

493. (New) The liquid pharmaceutical composition of Claim 490 wherein the aqueous medium comprises water.

494. (New) The liquid pharmaceutical composition as recited in Claim 490 wherein the dosage form is a powder and the aqueous medium is water.

495. (New) The liquid pharmaceutical composition as recited in Claim 490 wherein the dosage form is a plurality of granules and the aqueous medium is water.



496. (New) A method of treating an acid-related gastrointestinal condition, comprising orally administering to a subject a solid pharmaceutical dosage form to a subject that is not enteric-coated or delayed-released, comprising:

- (a) lansoprazole; and
- (b) at least one buffering agent present in an amount sufficient to prevent or inhibit acid degradation of the lansoprazole by gastric acid so as to achieve bioavailability of the lansoprazole in the subject after oral administration of the dosage form.

497. (New) The method as recited in Claim 496 wherein the disorder is duodenal ulcer disease.

498. (New) The method as recited in Claim 496 wherein the disorder is a gastric ulcer disease.

499. (New) The method as recited in Claim 496 wherein the disorder is gastroesophageal reflux disease (GERD).

500. (New) The method as recited in Claim 496 wherein the disorder is erosive esophagitis.

501. (New) The method as recited in Claim 496 wherein the disorder is poorly responsive symptomatic GERD.

502. (New) The method as recited in Claim 496 wherein the disorder is a pathological hypersecretory disease.

503. (New) The method as recited in Claim 496 wherein the disorder is Zollinger Ellison Syndrome.

504. (New) The method as recited in Claim 496 wherein the disorder is dyspepsia.

505. (New) The method as recited in Claim 496 wherein the lansoprazole comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

506. (New) The method as recited in Claim 496 wherein the dosage form further comprises a flavoring agent.

507. (New) The method as recited in Claim 496 wherein the dosage form further comprises an anti-foaming agent.

508. (New) The method as recited in Claim 496 wherein the lansoprazole is present in an amount of about 10 mg to about 60 mg.

509. (New) The method as recited in Claim 496 wherein the dosage form is a tablet.

510. (New) The method as recited in Claim 496 wherein the dosage form is a powder.

511. (New) The method as recited in Claim 496 wherein the dosage form is a suspension tablet.

512. (New) The method as recited in Claim 496 wherein the dosage form is a chewable tablet.

513. (New) The method as recited in Claim 512 wherein the chewable table further comprises aspartame.

514. (New) The method as recited in Claim 496 wherein the dosage form is a capsule.
515. (New) The method as recited in Claim 496 wherein the dosage form is an effervescent powder.
516. (New) The method as recited in Claim 496 wherein the dosage form is an effervescent tablet.
517. (New) The method as recited in Claim 496 wherein the dosage form is a plurality of pellets.
518. (New) The method as recited in Claim 496 wherein the dosage form is a plurality of granules.
519. (New) The method as recited in Claim 496 wherein the buffering agent is present in an amount of about 4 mEq to about 30 mEq.
520. (New) The method as recited in Claim 496 wherein the buffering agent is present in an amount of about 7.5 mEq to about 15 mEq.
521. (New) The method as recited in Claim 496 wherein the buffering agent is present in an amount of about 10 mEq to about 20 mEq.
522. (New) The method as recited in Claim 496 wherein the buffering agent comprises a bicarbonate salt of a Group IA metal.
523. (New) The method as recited in Claim 496 wherein the buffering agent comprises sodium bicarbonate.

524. (New) The method as recited in Claim 496 wherein the buffering agent comprises about 250 mg to about 1680 mg sodium bicarbonate.

525. (New) The method as recited in Claim 496 wherein the buffering agent comprises about 840 mg to about 1680 mg sodium bicarbonate.

526. (New) The method as recited in Claim 496 wherein the buffering agent comprises calcium carbonate.

527. (New) The method as recited in Claim 496 wherein the buffering agent comprises about 250 mg to about 1000 mg calcium carbonate.

528. (New) The method as recited in Claim 496 wherein the buffering agent comprises about 500 mg to about 1000 mg calcium carbonate.

529. (New) The method as recited in Claim 496 wherein the buffering agent comprises a combination of calcium carbonate and sodium bicarbonate.

530. (New) The method as recited in Claim 496 wherein the buffering agent comprises at least one of magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium silicate, magnesium lactate and other magnesium salts.

531. (New) The method as recited in Claim 496 wherein the buffering agent comprises at least one of calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, calcium gluconate, calcium glycinate, calcium maleate, and other calcium salts.

532. (New) A composition, comprising:

- (a) lansoprazole;
- (b) gastric secretions; and
- (c) at least one buffering agent present in an amount sufficient to prevent or inhibit acid degradation of the lansoprazole by the gastric secretions so as to achieve bioavailability of the lansoprazole in a subject,

wherein the lansoprazole and the buffering agent comprise a solid dosage form, which is capable of disintegration and dissolution in the gastric secretions and is not enteric-coated or delayed-released.

9, 533. (New) The composition as recited in Claim 532 wherein the lansoprazole comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

534. (New) The composition as recited in Claim 532 wherein the lansoprazole is present in a therapeutically effective amount.

535. (New) The composition as recited in Claim 532 wherein the lansoprazole is present in an amount of about 10 mg to about 60 mg.

536. (New) The composition as recited in Claim 532 wherein the dosage form is a tablet.

537. (New) The composition as recited in Claim 532 wherein the dosage form is a powder.

538. (New) The composition as recited in Claim 532 wherein the dosage form is a suspension tablet.

539. (New) The composition as recited in Claim 532 wherein the dosage form is a chewable tablet.

540. (New) The composition as recited in Claim 539 wherein the chewable tablet further comprises aspartame.

541. (New) The composition as recited in Claim 532 wherein the dosage form is a capsule.

542. (New) The composition as recited in Claim 532 wherein the dosage form is an effervescent powder.

543. (New) The composition as recited in Claim 532 wherein the dosage form is an effervescent tablet.

544. (New) The composition as recited in Claim 532 wherein the dosage form is a plurality of pellets.

545. (New) The composition as recited in Claim 532 wherein the dosage form is a plurality of granules.

546. (New) The composition as recited in Claim 532 wherein the buffering agent is present in an amount of about 4 mEq to about 30 mEq.

547. (New) The composition as recited in Claim 532 wherein the buffering agent is present in an amount of about 7.5 mEq to about 15 mEq.

548. (New) The composition as recited in Claim 532 wherein the buffering agent is present in an amount of about 10 mEq to about 20 mEq.

549. (New) The composition as recited in Claim 532 wherein the buffering agent comprises sodium bicarbonate.

550. (New) The composition as recited in Claim 532 wherein the buffering agent comprises about 250 mg to about 1680 mg sodium bicarbonate.

551. (New) The composition as recited in Claim 532 wherein the buffering agent comprises about 840 mg to about 1680 mg sodium bicarbonate.

552. (New) The composition as recited in Claim 532 wherein the buffering agent comprises calcium carbonate.

553. (New) The composition as recited in Claim 532 wherein the buffering agent comprises about 250 mg to about 1000 mg calcium carbonate.

554. (New) The composition as recited in Claim 532 wherein the buffering agent comprises about 500 mg to about 1000 mg calcium carbonate.

555. (New) The composition as recited in Claim 532 wherein the buffering agent comprises a combination of calcium carbonate and sodium bicarbonate.

556. (New) The composition as recited in Claim 532 wherein the buffering agent comprises at least one of magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium silicate, magnesium lactate and other magnesium salts.

557. (New) The composition as recited in Claim 532 wherein the buffering agent comprises at least one of calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, calcium gluconate, calcium glycinate, calcium maleate, and other calcium salts.

558. (New) The composition as recited in Claim 532 further comprising a flavoring agent.

559. (New) The composition as recited in Claim 532 further comprising an anti-foaming agent.

560. (New) A solid pharmaceutical dosage form that is not enteric-coated or delayed-released, comprising:

- (a) a first part comprising lansoprazole; and
- (b) a second part surrounding the first part, the second part comprising at least one buffering agent present in an amount sufficient to prevent or inhibit acid degradation of the lansoprazole by gastric acid so as to achieve bioavailability of the lansoprazole in a subject after oral administration of the dosage form.

561. (New) The dosage form as recited in Claim 560 wherein the bioavailability of the lansoprazole is sufficient to elicit a therapeutic effect.

562. (New) The dosage form as recited in Claim 560 wherein the lansoprazole is present in a therapeutically effective amount.

563. (New) The dosage form as recited in Claim 560 wherein the lansoprazole comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

564. (New) The dosage form as recited in Claim 560 wherein the first part comprises a compressed tablet.

565. (New) The dosage form as recited in Claim 564 wherein the second part further comprises a capsule which surrounds the buffering agent and the tablet.

566. (New) The dosage form as recited in Claim 560 wherein the first part further comprises a capsule containing the lansoprazole and the second part further comprises a capsule containing the capsule of the first part.

567. (New) The dosage form as recited in Claim 560 wherein the buffering agent comprises a bicarbonate salt of a Group IA metal.

568. (New) The dosage form as recited in Claim 560 wherein the buffering agent comprises at least one of magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium silicate, magnesium lactate and other magnesium salts.

569. (New) The dosage form as recited in Claim 560 wherein the buffering agent comprises at least one of calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, calcium gluconate, calcium glycinate, calcium maleate, and other calcium salts.

570. (New) The dosage form as recited in Claim 560 wherein the buffering agent is about 250 mg to about 1680 mg sodium bicarbonate.

571. (New) The dosage form as recited in Claim 560 wherein the buffering agent is about 840 mg to about 1680 mg sodium bicarbonate.

572. (New) The dosage form as recited in Claim 560 wherein the buffering agent comprises about 250 mg to about 1000 mg calcium carbonate.

573. (New) The dosage form as recited in Claim 560 wherein the buffering agent is about 500 mg to about 100 mg calcium carbonate.

574. (New) The dosage form as recited in Claim 560 wherein the buffering agent comprises a combination of sodium bicarbonate and calcium carbonate.

575. (New) A method of treating an acid-related gastrointestinal condition, comprising orally administering to a subject a solid pharmaceutical dosage form that is not enteric-coated or delayed-released, comprising:

- (a) a first part comprising lansoprazole; and
- (b) a second part surrounding the first part, the second part comprising at least one buffering agent present in an amount sufficient to prevent or inhibit acid degradation of the lansoprazole by gastric acid so as to achieve bioavailability of the lansoprazole in the subject after oral administration of the dosage form.

576. (New) The method as recited in Claim 575 wherein the disorder is duodenal ulcer disease.

577. (New) The method as recited in Claim 575 wherein the disorder is a gastric ulcer disease.

578. (New) The method as recited in Claim 575 wherein the disorder is gastroesophageal reflux disease (GERD).

579. (New) The method as recited in Claim 575 wherein the disorder is erosive esophagitis.

580. (New) The method as recited in Claim 575 wherein the disorder is poorly responsive symptomatic GERD.

581. (New) The method as recited in Claim 575 wherein the disorder is a pathological hypersecretory disease.

582. (New) The method as recited in Claim 575 wherein the disorder is Zollinger Ellison Syndrome.

583. (New) The method as recited in Claim 575 wherein the disorder is dyspepsia.

584. (New) The method as recited in Claim 575 wherein the lansoprazole comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

585. (New) The method as recited in Claim 575 wherein the first part comprises a compressed tablet.

586. (New) The method as recited in Claim 585 wherein the second part further comprises a capsule which surrounds the buffering agent and the tablet.

587. (New) The method as recited in Claim 575 wherein the first part further comprises a capsule containing the lansoprazole, and the second part further comprises a capsule containing the capsule of the first part.

588. (New) The method as recited in Claim 575 wherein the buffering agent is present in an amount of about 4 mEq to about 30 mEq.

589. (New) The method as recited in Claim 575 wherein the buffering agent is present in an amount of about 7.5 mEq to 15 mEq.

590. (New) The method as recited in Claim 575 wherein the buffering agent is present in an amount of about 10 mEq to about 20 mEq.

591. (New) A solid pharmaceutical dosage form, comprising:

(a) a first part comprising lansoprazole that is in an enteric-coated or delayed-released form; and

(b) a second part contacting the first part, the second part comprising at least one buffering agent present in an amount of about 4 mEq to about 30 mEq.

592. (New) The dosage form as recited in Claim 591 wherein the buffering agent is present in an amount of about 7.5 mEq to about 15 mEq.

593. (New) The dosage form as recited in Claim 591 wherein the buffering agent is present in an amount of about 10 mEq to about 20 mEq.

594. (New) The dosage form as recited in Claim 591 wherein the bioavailability of the lansoprazole is sufficient to elicit a therapeutic effect.

595. (New) The dosage form as recited in Claim 591 wherein the lansoprazole is present in a therapeutically effective amount.

596. (New) The dosage form as recited in Claim 591 wherein the lansoprazole comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

597. (New) The dosage form as recited in Claim 591 wherein the lansoprazole comprises enteric coated granules, which surround an inner core of the second part, the second part further comprising a non-enteric-coated lansoprazole.

598. (New) The dosage form as recited in Claim 591 wherein the first part further comprises a non-enteric-coated lansoprazole.

599. (New) The dosage form as recited in Claim 591 wherein the first part further comprises a non-enteric-coated lansoprazole and the second part surrounds the first part.

600. (New) The dosage form as recited in Claim 591 wherein the first part is a tablet.

601. (New) The dosage form as recited in Claim 600 wherein the second part further comprises a capsule which surrounds the buffering agent and the tablet.

602. (New) The dosage form as recited in Claim 600 wherein the first part further comprises a capsule containing the lansoprazole, and the second part further comprises a capsule containing the capsule of the first part.

603. (New) The dosage form as recited in Claim 600 wherein the buffering agent comprises about 250 mg to about 1680 mg sodium bicarbonate.

604. (New) The dosage form as recited in Claim 600 wherein the buffering agent comprises about 840 mg to about 1680 mg sodium bicarbonate.

605. (New) The dosage form as recited in Claim 600 wherein the buffering agent comprises about 250 mg to about 1000 mg calcium carbonate.

606. The dosage form as recited in Claim 600 wherein the buffering agent comprises about 500 mg to about 1000 mg calcium carbonate.

607. (New) The dosage form as recited in Claim 600 wherein the buffering agent comprises a combination of sodium bicarbonate and calcium carbonate.

608. (New) The dosage form as recited in Claim 600 wherein the buffering agent comprises at least one of magnesium hydroxide, magnesium lactate, magnesium gluconate, magnesium oxide, magnesium carbonate, magnesium silicate, magnesium lactate and other magnesium salts.

609. (New) The dosage form as recited in Claim 600 wherein the buffering agent comprises at least one of calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide, calcium lactate, calcium carbonate, calcium bicarbonate, calcium gluconate, calcium glycinate, calcium maleate, and other calcium salts.

610. (New) The dosage form as recited in Claim 600 wherein the second part surrounds the first part and wherein the second part further comprises non-enteric-coated lansoprazole.

611. (New) A method of treating an acid-related gastrointestinal condition, comprising orally administering to a subject a solid pharmaceutical dosage form, comprising:

(a) a first part comprising lansoprazole that is in an enteric-coated or delayed-released form; and

(b) a second part contacting the first part, the second part comprising at least one buffering agent present in an amount of about 4 mEq to about 30 mEq.

612. (New) The method as recited in Claim 611 wherein the buffering agent is present in an amount of about 7.5 mEq to about 15 mEq.

613. (New) The method as recited in Claim 611 wherein the buffering agent is present in an amount of about 10 mEq to about 20 mEq.

614. (New) The method as recited in Claim 611 wherein the lansoprazole comprises a substantially pure enantiomer, a racemic mixture, a derivative, or a base or salt thereof.

615. (New) The method as recited in Claim 611 wherein the lansoprazole comprises enteric coated granules, which surround an inner core of the second part, the second part further comprising a non-enteric-coated lansoprazole.

616. (New) The method as recited in Claim 611 wherein the first part further comprises a non-enteric-coated lansoprazole.

617. (New) The method as recited in Claim 611 wherein the first part further comprises a non-enteric-coated lansoprazole and the second part surrounds the first part.

618. (New) The method as recited in Claim 611 wherein the first part is a tablet.

619. (New) The method as recited in Claim 618 wherein the second part further comprises a capsule which surrounds the buffering agent and the tablet.

620. (New) The method as recited in Claim 611 wherein the first part further comprises a capsule containing the lansoprazole, and the second part further comprises a capsule containing the capsule of the first part.

621. (New) The method as recited in Claim 611 wherein the second part surrounds the first part and wherein the second part further comprises non-enteric-coated lansoprazole.